Clinical trial NCT04095975: Effectiveness of Urinary Alkalinizing Agents on Kidney Stone Risk
Official title: Effectiveness of Prescription vs. Non-prescription Urinary Alkalinizing Agents on Kidney Stone Risk
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Kidney Stone
Lead sponsor: University of Wisconsin, Madison
Sponsor class: OTHER
First posted: 2019-09-19
Enrollment: 31
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Randomized treatment trial of baking soda or LithoLyte to determine if baking soda and Litholyte are effective in raising 24 hour urine citrate and pH.

Detailed description: Participants will not be required to attend any study visits outside of normal clinical encounters. Participants enrolled in the study will be randomized to treatment upon enrollment. Blocked randomization will be conducted, utilizing sex (M/F) and recurrent stone former (Y/N) as algorithm variables.

Participants randomized to LithoLyte® will be provided 40 mEq of alkali in the form of LithoLyte® and advised to take 20 mEq twice daily according to package instructions, once in morning and once at bedtime; no requirements about proximity to meals are necessary.

Participants randomized to baking soda will be provided instructions for using baking soda to provide 40 mEq alkali, to be accomplished by dissolving ¼ teaspoon baking soda in water or other beverage (any amount) in the morning on an empty stomach and ½ teaspoon baking soda in water or other beverage again at bedtime, also on an empty stomach.

The 24-hour urine results that are available upon enrollment will be used for pre-intervention values. The 24-hour results from each participant's followup collection will be used for post-intervention values. Thus, no extra encounters are required for participation in the study. Additionally, no extra tests are required for participation in the study as participants would normally complete a post-treatment 24-hour urine collection anyway. Participants will be screened for eligibility, i.e., by pre-clinic review of schedules and 24-hour urine results. Only those meeting inclusion criteria will be invited to participate and enrolled, provided that informed consent is provided by signing the signature page of the consent/authorization form. The treatment/intervention period is up to 90 days (approximately 3 months). However, it should be noted that, as these are clinical interventions that would be prescribed or recommended anyway, it is expected that participants will continue treatment indefinitely and under supervision of urology and/or Metabolic Stone Clinic providers. If the participant has failed the randomized therapy they are assigned to, they will be clinically assigned a different treatment option and continue to be followed up in routine fashion.

Participants will also be asked to complete a medication questionnaire and log, as well as the Wisconsin Stone Quality of Life (WISQOL) questionnaire. All study procedures are considered standard of care, except for: randomization into treatment and the medication questionnaire and log.

Protocol Amendment Approved 11/16/2020 removed the UrocitK study arm; the investigators faced challenges recruiting participants during the COVID-19 pandemic and the possibility of being randomized into a prescription drug arm was causing many potential participants to choose not to participate.

Eligibility criteria: Inclusion Criteria:

* Must be suitable for the study per clinical judgement of study team members
* Patient in the UW Health University Hospital Urology Clinic or the Metabolic Stone Clinic
* Had at least one kidney stone event
* Greater than or equal to 18 years of age
* 24 hour urine citrate is less than 420 mg and/or urine pH is less than 5.9
* Urinary alkalinization is deemed by provider as a necessary therapeutic goal for the subject and may be achieved by any of the three therapies under examination
* Subject is willing to provide consent and to be randomized into a treatment

Exclusion Criteria:

* Subject is deemed unsuitable for urinary alkalinizing therapy by study staff
* Subject is already on a urinary alkalinizing agent
* Subject is on acetazolamide
* Subject reports sensitivity to sugar alcohols
* Subject is under 18 years of age
* Subject has not completed a 24 hour urine collection within 6 months
* Subject is pregnant or breastfeeding
* Subject is unable or unwilling to provide consent
* Subject is unable or unwilling to be randomized
* Subject reports they are unwilling or unable to use measuring device required in the baking soda arm of the study

Primary outcomes:
measure: Change in 24 hour urine citrate
timeFrame: Pre and 24 hour post intervention (up to 90 days)
measure: Change in 24 hour urine pH
timeFrame: Pre and 24 hour post intervention (up to 90 days)
Secondary outcomes:
measure: Post-intervention 24-hour urine calcium
timeFrame: Enrollment and follow up visit (approximately 90 days)
measure: 24 hour urine calcium
timeFrame: Enrollment and follow up visit (approximately 90 days)
measure: Post interventional 24 hour urine supersaturation indices for calcium oxalate
timeFrame: Enrollment and follow up visit (approximately 90 days)
measure: Post interventional 24 hour urine supersaturation indices for calcium phosphatase
timeFrame: Enrollment and follow up visit (approximately 90 days)
measure: Cost of Treatment as measured by USD spent on the interventional drug
timeFrame: End of study (approximately 90 days)
measure: Patient acceptability
timeFrame: End of study (approximately 90 days)
Other outcomes:
Locations:
city: Madison
country: United States
facility: UW-Madison
state: Wisconsin
Study officials:
affiliation: University of Wisconsin, Madison
name: Kristina L Penniston, PhD, RDN, FAND
role: PRINCIPAL_INVESTIGATOR
References: